Skip to main content

Table 5 Individual symptoms

From: Effectiveness, safety and tolerability of a complex homeopathic medicinal product in the prevention of recurrent acute upper respiratory tract infections in children: a multicenter, open, comparative, randomized, controlled clinical trial

Individual symptoms

Visit

Absence of symptom

χ 2-Test

CalSuli-4-02 N = 99

Control N = 101

(df) statistics

p

N

%

N

%

Fever

Baseline (day 0)

82

82.8

79

78.2

-

-

2nd FU (day 21)

94

95.0

94

93.1

(1) 0.380

0.5377

3rd FU (3 months p-t)

93

93.9

92

91.1

(1) 0.803

0.3701

Termination (6 months p-t)

96

97.0

98

97.0

(1) 0.000

0.9884

Nasal discharge (rhinorrhea/mucopurulent)

Baseline (day 0)

42

42.4

46

45.5

-

-

2nd FU (day 21)

82

82.8

86

85.2

(2) 0.218

0.8968

3rd FU (3 months p-t)

84

84.9

86

85.2

(1) 0.003

0.9554

Termination (6 months p-t)

90

90.9

92

91.1

(2) 1.079

0.5832

Skin pallor

Baseline (day 0)

42

42.4

37

36.6

-

-

2nd FU (day 21)

65

65.7

55

54.5

(1) 2.660

0.1029

3rd FU (3 months p-t)

74

74.8

66

65.4

(1) 2.223

0.1360

Termination (6 months p-t)

80

80.8

73

72.3

(1) 2.184

0.1395

Rales in lungs

Baseline (day 0)

87

87.9

87

86.1

-

-

2nd FU (day 21)

97

98.0

98

97.0

(2) 2.985

0.2248

3rd FU (3 months p-t)

95

96.0

92

91.1

(1) 2.806

0.0939

Termination (6 months p-t)

97

98.0

97

96.0

(1) 1.980

0.1594

Restlessness for unknown reason

Baseline (day 0)

77

77.8

85

84.2

-

-

2nd FU (day 21)

91

91.9

94

93.1

(2) 1.362

0.5061

3rd FU (3 months p-t)

97

98.0

97

96.0

(1) 1.980

0.1594

Termination (6 months p-t)

94

95.0

97

96.0

(2) 1.027

0.5985

Atopic dermatitis manifestations

Baseline (day 0)

61

61.6

66

65.4

-

-

2nd FU (day 21)

73

73.7

72

71.3

(2) 0.675

0.7137

3rd FU (3 months p-t)

82

82.8

76

75.3

(3) 3.208

0.3607

Termination (6 months p-t)

88

88.9

81

80.2

(3) 5.070

0.1667

Child’s activities impairment

Baseline (day 0)

63

63.6

71

70.3

-

-

2nd FU (day 21)

93

93.9

82

81.2

(2) 8.218

0.0164

3rd FU (3 months p-t)

92

92.9

87

86.1

(1) 3.002

0.0832

Termination (6 months p-t)

95

96.0

87

86.1

(1) 7.475

0.0063

  1. Df degree of freedom, FU follow-up, p-t post-treatment, χ 2 chi-square, ITT intention-to-treat analysis